// Company Overview //
| Stock Name | 友芝友生物－Ｂ |
|---|---|
| Stock Code | 02496 |
| Company Full Name | 友芝友生物－Ｂ |
| Industry | 醫療保健 |
| Principal Activities | 公司是一家致力于開發用于治療癌癥相關并發癥、癌癥及老年性眼科疾病的BsAb療法的生物技術公司。 |
| Listing Date | 2023-09-25 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | No data |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國湖北省武漢市東湖新技術開發區高新大道666號 |
| Business Address (Hong Kong) | No data |
| Place of Incorporation | No data |
| Listing Method | No data |
| Listing Board | Main Board |
| Website | https://www.yzybio.com/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
// Offering Information //
| Offering Mechanism | 未知 |
|---|---|
| Clawback Tiers | No data |
| Prospectus Date | 2023-09-13 |
| Offer Price | HK$ 16.00 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 200 shares |
| Entry Threshold | HK$ 3,200 |
| Par Value | No data |
| Global Offering Shares | — |
| HK Public Offering Shares | — (0%) |
| International Placing Shares | — (0%) |
| Offer Ratio | No data |
| Total Shares Post-IPO | No data |
| Total Global Offering Size | HK$ — |
| Public Offering Size | HK$ — (0%) |
| Oversubscription Multiple | —x |
| Valid Applications | — |
| Accepted Applications | — |
| Reallocation | No |
| Total Funds Raised | HK$ 17,603,200 |
| Greenshoe (Over-allotment Option) | No data |
// Valuation & Financials //
| Market Cap (at Offer Price) | HK$ 0 |
|---|---|
| Pre-IPO Valuation (Last Round) | No data |
| P/E Ratio | -14.65 |
| Profit/Loss Status | No data |
| Period-End Cash Balance | No data |
| Listing Expenses | ~HK$ 55,600,000 |
| Listing Expenses / Funds Raised | No data |
| Total Pre-IPO Investment | No data |
// First Day Performance
| First Day Close | Loading... |
|---|---|
| First Day Open | HK$ 16.4 |
| First Day Change | -67.75% |
| First Day Volume | 1519600.0 |
| First Day Turnover | 24912300.0 |
// Price Chart //
Loading...
// Use of Proceeds
| Use of Proceeds | 1、約80%或約97.1百萬港元將用作核心產品M701計劃進行的臨床試驗、擬備注冊備案文件及商業化推出計劃； 2、約12%或14.6百萬港元將用作Y101D計劃進行的臨床試驗； 3、約8%或9.7百萬港元將用作營運資金和一般公司用途。 |
|---|
// Underwriting Syndicate //
独家保荐人 (1)
中信建投（国际）融资有限公司
整体协调人 (3)
中信建投（国际）融资有限公司
国泰君安证券（香港）有限公司
建银国际金融有限公司
联席账簿管理人 (6)
中信建投（国际）融资有限公司
国泰君安证券（香港）有限公司
建银国际金融有限公司
中银国际亚洲有限公司
天风国际证券与期货有限公司
中国银河国际证券（香港）有限公司
联席牵头经办人 (8)
中信建投（国际）融资有限公司
国泰君安证券（香港）有限公司
建银国际金融有限公司
中银国际亚洲有限公司
天风国际证券与期货有限公司
中国银河国际证券（香港）有限公司
利弗莫尔证券有限公司
富途证券国际（香港）有限公司
// Cornerstone Investors //
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 成都朴华凯智生物科技有限公司 | 21,481,600 HKD | — | 12.20% | — | 6 months | 2024-03-25 |
| 2 | 武汉光谷健康产业投资有限公司 | 42,976,000 HKD | — | 24.42% | — | 6 months | 2024-03-25 |
| 3 | 武汉市楚兴友瑞大健康产业投资基金合伙企业(有限合伙) | 39,763,200 HKD | — | 22.59% | — | 6 months | 2024-03-25 |
// Directors & Management //
| Chairman | Zhou Pengfei |
|---|---|
| Company Secretary | 鄭建華;賴天恩 |
No director data available.
// Major Shareholders //
| Major Shareholders & Holdings | 袁謙(10.57%);武漢才智投資管理合伙企業(有限合伙)(8.70%);周宏峰(5.28%) |
|---|
// Allotment Benchmarks //
Pool A (Small Subscriptions)
| Shares Applied | Applicants | Allottees | Expected Lots |
|---|---|---|---|
| 200 | 4,901 | 882 | 0.18 |
| 400 | 1,368 | 278 | 0.20 |
| 600 | 215 | 47 | 0.22 |
| 800 | 119 | 28 | 0.24 |
| 1,000 | 291 | 85 | 0.29 |
| 1,200 | 53 | 18 | 0.34 |
| 1,400 | 57 | 22 | 0.39 |
| 1,600 | 39 | 16 | 0.41 |
| 1,800 | 29 | 12 | 0.41 |
| 2,000 | 1,410 | 592 | 0.42 |
| 3,000 | 91 | 55 | 0.60 |
| 4,000 | 83 | 63 | 0.76 |
| 5,000 | 37 | 33 | 0.89 |
| 6,000 | 10 | 10 | 1.00 |
| 7,000 | 7 | 1 | 1.14 |
| 8,000 | 22 | 4 | 1.18 |
| 9,000 | 121 | 34 | 1.28 |
| 10,000 | 42 | 17 | 1.41 |
| 15,000 | 16 | 1 | 2.06 |
| 20,000 | 18 | 13 | 2.72 |
| 25,000 | 7 | 2 | 3.29 |
| 30,000 | 7 | 6 | 3.85 |
| 35,000 | 1 | 1 | 4.01 |
| 40,000 | 3 | 1 | 4.34 |
| 50,000 | 5 | 5 | 5.00 |
| 60,000 | 10 | 7 | 5.70 |
Allotment Benchmarks
